RNA-seq profiling of MED patient-derived (MATN3 V194D) and unaffected iPSC-chondrogenesis
PBMCs from MED patients carrying the MATN3 V194D mutation and unaffected controls were reprogrammed into hiPSCs. Samples were differentiated into Day 21 cartilage pellets via an iMSC intermediate.